Literature DB >> 21512729

Anthracyclines for acute lymphoblastic leukemia in a child with congenital long QT syndrome.

Sachiko Sasase1, Hisao Yoshida1, Risa Matsumura1, Emiko Miyashita1, Yoshiko Hashii1, Hideaki Ohta2, Shu Maekawa1, Shigetoyo Kogaki1, Keiichi Ozono1.   

Abstract

Anthracyclines are key drugs for the treatment of children with acute lymphoblastic leukemia (ALL). However, anthracyclines are known to induce QT prolongation, and life-threatening complications, such as torsades de pointe may also occur. To date, there have been no reports on the use of anthracyclines in patients with congenital long QT syndrome (LQTS). We report a child with ALL complicated by congenital LQTS who was treated with anthracyclines. The administration of anthracyclines caused QT-interval prolongation, but this was uneventful with the concomitant administration of magnesium sulfate.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21512729     DOI: 10.1007/s12185-011-0851-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  21 in total

1.  Successful uses of magnesium sulfate for torsades de pointes in children with long QT syndrome.

Authors:  Kenji Hoshino; Kiyoshi Ogawa; Takashi Hishitani; Takeshi Isobe; Yoshikatsu Etoh
Journal:  Pediatr Int       Date:  2006-04       Impact factor: 1.524

Review 2.  Chloride conductance pathways in heart.

Authors:  J R Hume; R D Harvey
Journal:  Am J Physiol       Date:  1991-09

3.  Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel.

Authors:  M C Sanguinetti; M E Curran; A Zou; J Shen; P S Spector; D L Atkinson; M T Keating
Journal:  Nature       Date:  1996-11-07       Impact factor: 49.962

Review 4.  Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS.

Authors:  D M Roden; R Lazzara; M Rosen; P J Schwartz; J Towbin; G M Vincent
Journal:  Circulation       Date:  1996-10-15       Impact factor: 29.690

5.  Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: reversal by magnesium.

Authors:  S C Verduyn; M A Vos; J van der Zande; F F van der Hulst; H J Wellens
Journal:  Cardiovasc Res       Date:  1997-06       Impact factor: 10.787

6.  Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2.

Authors:  I Splawski; J Shen; K W Timothy; M H Lehmann; S Priori; J L Robinson; A J Moss; P J Schwartz; J A Towbin; G M Vincent; M T Keating
Journal:  Circulation       Date:  2000-09-05       Impact factor: 29.690

7.  Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks).

Authors:  Joffrey Ducroq; H Moha ou Maati; S Guilbot; S Dilly; E Laemmel; C Pons-Himbert; J F Faivre; P Bois; O Stücker; M Le Grand
Journal:  Br J Pharmacol       Date:  2009-08-24       Impact factor: 8.739

Review 8.  Long QT syndrome.

Authors:  Ilan Goldenberg; Arthur J Moss
Journal:  J Am Coll Cardiol       Date:  2008-06-17       Impact factor: 24.094

9.  Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.

Authors:  Allen R Chauvenet; Paul L Martin; Meenakshi Devidas; Stephen B Linda; Beverly A Bell; Joanne Kurtzberg; Jeanette Pullen; Mark J Pettenati; Andrew J Carroll; Jonathan J Shuster; Bruce Camitta
Journal:  Blood       Date:  2007-04-18       Impact factor: 22.113

10.  The associations of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study).

Authors:  H Tsuji; F J Venditti; J C Evans; M G Larson; D Levy
Journal:  Am J Cardiol       Date:  1994-08-01       Impact factor: 2.778

View more
  1 in total

Review 1.  Educational paper: decreasing the burden of cardiovascular disease in childhood cancer survivors: an update for the pediatrician.

Authors:  Rejane F Dillenburg; Paul Nathan; Luc Mertens
Journal:  Eur J Pediatr       Date:  2013-01-30       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.